The efficacy and safety of the addition of programmed cell death protein 1 inhibitor to preoperative chemotherapy in locoregionally advanced oropharyngeal carcinoma.

IF 1.5 4区 医学 Q4 ONCOLOGY
Translational cancer research Pub Date : 2025-02-28 Epub Date: 2025-02-26 DOI:10.21037/tcr-2025-202
Guan-Zhong Lu, Zhi-Cong Hong, Yi-Feng Yu, Lin-Feng Guo, Daniel T Ginat, San-Gang Wu, Li-Mei Guan
{"title":"The efficacy and safety of the addition of programmed cell death protein 1 inhibitor to preoperative chemotherapy in locoregionally advanced oropharyngeal carcinoma.","authors":"Guan-Zhong Lu, Zhi-Cong Hong, Yi-Feng Yu, Lin-Feng Guo, Daniel T Ginat, San-Gang Wu, Li-Mei Guan","doi":"10.21037/tcr-2025-202","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors have shown promise in improving the survival rates for recurrent and/or metastatic head and neck cancers. However, their impact on curative outcomes in head and neck cancers remains undefined, especially for those with locoregionally advanced oropharyngeal carcinoma (LAOPC), a subtype of head-and-neck malignancy closely associated with human papillomavirus infection. This study aimed to clarify the efficacy and safety of the addition of programmed cell death protein 1 (PD-1) inhibitor into preoperative chemotherapy in LAOPC.</p><p><strong>Methods: </strong>We retrospectively included patients with LAOPC who underwent preoperative immunochemotherapy between 2021 and 2024. Statistical analyses were conducted using chi-square tests. The efficacy was assessed using Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1). Safety was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) 5.0.</p><p><strong>Results: </strong>A total of 23 patients were identified, and 11 (47.8%) had P16-positive tumors. There were 22 patients (95.7%) who completed two cycles of preoperative treatment. Among the 23 patients, the response to primary tumors and neck metastatic lymph nodes could be assessed in 21 and 22 patients, respectively. Additionally, 13 (61.9%) patients had a major pathologic response to the primary tumor, including 12 patients (57.1%) who achieved a pathologic complete response (PCR). In addition, 11 (50.0%) patients had a PCR in the metastatic cervical lymph nodes, while 11 (50.0%) patients still had residual tumors in the lymph nodes. The combined positive score and P16 status were not significantly associated with PCR to the primary tumor or neck metastatic lymph nodes. Moreover, 19 (82.6%) patients experienced treatment-related adverse effects, with the majority being grade 1-2 toxicities, and only 2 (8.7%) patients had grade 3 or higher toxicities. No treatment-related deaths occurred.</p><p><strong>Conclusions: </strong>The incorporation of a PD-1 inhibitor into preoperative chemotherapy may be an effective approach for treating LAOPC and involve acceptable toxicity.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"1401-1414"},"PeriodicalIF":1.5000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912034/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-2025-202","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/26 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Immune checkpoint inhibitors have shown promise in improving the survival rates for recurrent and/or metastatic head and neck cancers. However, their impact on curative outcomes in head and neck cancers remains undefined, especially for those with locoregionally advanced oropharyngeal carcinoma (LAOPC), a subtype of head-and-neck malignancy closely associated with human papillomavirus infection. This study aimed to clarify the efficacy and safety of the addition of programmed cell death protein 1 (PD-1) inhibitor into preoperative chemotherapy in LAOPC.

Methods: We retrospectively included patients with LAOPC who underwent preoperative immunochemotherapy between 2021 and 2024. Statistical analyses were conducted using chi-square tests. The efficacy was assessed using Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1). Safety was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) 5.0.

Results: A total of 23 patients were identified, and 11 (47.8%) had P16-positive tumors. There were 22 patients (95.7%) who completed two cycles of preoperative treatment. Among the 23 patients, the response to primary tumors and neck metastatic lymph nodes could be assessed in 21 and 22 patients, respectively. Additionally, 13 (61.9%) patients had a major pathologic response to the primary tumor, including 12 patients (57.1%) who achieved a pathologic complete response (PCR). In addition, 11 (50.0%) patients had a PCR in the metastatic cervical lymph nodes, while 11 (50.0%) patients still had residual tumors in the lymph nodes. The combined positive score and P16 status were not significantly associated with PCR to the primary tumor or neck metastatic lymph nodes. Moreover, 19 (82.6%) patients experienced treatment-related adverse effects, with the majority being grade 1-2 toxicities, and only 2 (8.7%) patients had grade 3 or higher toxicities. No treatment-related deaths occurred.

Conclusions: The incorporation of a PD-1 inhibitor into preoperative chemotherapy may be an effective approach for treating LAOPC and involve acceptable toxicity.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
252
期刊介绍: Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信